AV
ARCH Venture Fund IX, L.P. disclosed a 17.4% stake in LYEL
ARCH Venture Fund IX, L.P. reported owning 17.4% of Lyell Immunopharma, Inc. (LYEL) (5,568,424 shares) in a Schedule 13G filed Nov 10, 2026.
A 13G is a passive stake: the holder does not plan to push for changes.
- Disclosed
- Nov 10, 2026
- Source
- Schedule 13G